Dana-Farber Cancer Institute | Strategic Alliance Partners

March 27, 2024

Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.

March 27, 2024

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

March 25, 2024

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

March 24, 2024

Mary-Ellen Taplin, MD, discusses ways to mitigate health care disparities in the treatment of patients with prostate cancer.

March 22, 2024

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

March 22, 2024

Anthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management

March 21, 2024

In the GENERATE study, 90% of those who viewed an online genetic education program chose to be tested for inherited predisposition to pancreatic cancer.

March 20, 2024

Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.

March 20, 2024

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

March 20, 2024

Mary-Ellen Taplin, MD, discusses strategies to mitigate health care inequities in prostate cancer.

March 18, 2024

The Third Transatlantic Exchange in Oncology Conference will focus on liquid biopsy as an emerging approach in precision cancer medicine.

March 18, 2024

Grant winner Tyler Miller, MD, PhD, outlines innovative plans for glioma research.

March 13, 2024

Drs Safah and Cutler discuss treatment practices for patients with steroid-refractory graft-vs-host disease and highlight patients who are steroid dependent.

March 13, 2024

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

March 12, 2024

The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.

March 09, 2024

Ko Un “Clara” Park, MD, discusses the FDA's vote in support of Lumisight for patients with breast cancer undergoing breast conserving surgery.

March 06, 2024

Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.

March 06, 2024

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

March 05, 2024

Different immunomodulatory mechanisms are at work depending on the type of treatment and the genetic makeup of the cancer in RCC.

February 29, 2024

The panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.